Victor Mandla Moyo

This inventor holds 44 USPTO granted patents and 64 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Polyglutamated Antifolates. Top assignees: L.e.a.f. Holdings Group LLC, Merrimack Pharmaceuticals, Inc., Ipsen Biopharm Limited. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Victor Mandla Moyo. Retrieved from https://idiyas.com/inventor/victor-mandla-moyo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 (Patent Applications = 64)

% Patents Active = 93.2

CIPO Patents = 4 (Patent Applications = 21)

EPO Patents = 9 (Patent Applications = 28)

Average Co-Inventor Count = 2.6

ph-index = 10

Forward Citations = 228(Granted Patents)

Location History:

Concord, MA (US) (2014 - 2016)
Ringoes, NJ (US) (2016 - 2024)

Company Filing History:

30 out of 30

L.e.a.f. Holdings Group LLC

patents

7 out of 54

Merrimack Pharmaceuticals, Inc.

patents

6 out of 46

Ipsen Biopharm Limited

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Polyglutamated Antifolates

Combination Therapy

Cancer Treatment

Targeted Therapies

Liposomal Gemcitabine

Pemetrexed

Antifolates

Pancreatic Cancer

Gamma Polyglutamated

Alpha Polyglutamated

Treatment Regimens

Platinum Complexes

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622874 - Trans-crocetin compositions and treatment regimens (2026-05-12),

2. 12458597 - Carotenoid compositions and uses thereof (2025-11-04),

3. 12433893 - Alpha polyglutamated pemetrexed and uses thereof (2025-10-07),

4. 12364691 - Methods for treating pancreatic cancer using combination therapies (2025-07-22),

5. 12350271 - Gamma polyglutamated aminopterin and uses thereof (2025-07-08),

6. 12336994 - Alpha polyglutamated tetrahydrofolates and uses thereof (2025-06-24),

7. 12310966 - Alpha polyglutamated aminopterin and uses thereof (2025-05-27),

8. 12296022 - D glutamate polyglutamated antifolates and uses thereof (2025-05-13),

9. 12290518 - Gamma polyglutamated methotrexate and uses thereof (2025-05-06),

10. 12246019 - Alpha polyglutamated lometrexol and uses thereof (2025-03-11),

11. 12246018 - Gamma polyglutamated pemetrexed and uses thereof (2025-03-11),

12. 12246015 - Alpha polyglutamated raltitrexed and uses thereof (2025-03-11),

13. 12239734 - Gamma polyglutamated raltitrexed and uses thereof (2025-03-04),

14. 12220431 - Gamma polyglutamated antifolates and uses thereof (2025-02-11),

15. 12213981 - Alpha polyglutamated pralatrexate and uses thereof (2025-02-04),

Title: Victor Mandla Moyo: Innovator in Anticancer Therapies

Introduction

Victor Mandla Moyo, based in Ringoes, NJ, is an accomplished inventor with a remarkable portfolio of 31 patents. His innovative work primarily focuses on the development of compositions and methods for treating hyperproliferative disorders, such as cancer, utilizing advanced formulations.

Latest Patents

Among his latest contributions to the field are two notable patents:

1. **Gamma polyglutamated raltitrexed and uses thereof** - This patent discloses gamma polyglutamated raltitrexed compositions, including innovative delivery vehicles like liposomes encapsulating the gamma polyglutamated raltitrexed. It outlines methods for creating and utilizing these compositions in treating hyperproliferative conditions and immune system disorders, such as inflammation and autoimmune diseases like rheumatoid arthritis.

2. **Gamma polyglutamated antifolates and uses thereof** - Similar in focus, this patent discusses gamma polyglutamated antifolate formulations, specifically those containing liposomes filled with the antifolate. It provides insights into the manufacturing processes and application methods for treating similar disorders as mentioned in the first patent.

Career Highlights

Throughout his career, Victor Moyo has contributed significantly to pharmaceutical innovations, particularly during his tenure with L.E.A.F. Holdings Group LLC and Merrimack Pharmaceuticals, Inc. His expertise in drug formulation and delivery systems has propelled advancements in treating complex medical conditions.

Collaborations

Victor has collaborated with notable professionals in the industry, including Clet Niyikiza and Jonathan Basil Fitzgerald. These partnerships have fostered a collaborative environment conducive to innovative research and development in the pharmaceutical field.

Conclusion

Victor Mandla Moyo’s extensive patent portfolio and his focus on innovative therapies illustrate his commitment to advancing medical science. His work not only addresses critical health challenges but also positions him as a key figure in the ongoing evolution of cancer treatment methodologies.

Profile summary based on public USPTO records.